• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AI Is Helping Cat Owners In Tokyo Keep Their Feline Friends Healthier: App Can Reportedly Detect Pain With More Than 95% Accuracy

    6/13/24 1:51:00 AM ET
    $BNAI
    $CDIO
    $NVDA
    EDP Services
    Technology
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $BNAI alert in real time by email

    Mayumi Kitakata, a 57-year-old resident of Tokyo, Japan, is among the many pet owners who have turned to artificial intelligence to ensure the well-being of their furry companions.

    What Happened: Kitakata, who is concerned about the health of her 14-year-old cat, Chi, has adopted CatsMe!, an AI-driven smartphone application that claims to detect feline pain, reported Reuters.

    Kitakata, who has had cats since her mid-20s, uses the app to monitor Chi’s urinal activity and facial expressions. She believes that if she had used CatsMe! with her previous cat, Soran, she might have been able to detect his cancer earlier and potentially save him.

    See Also: Apple Analyst Says ‘You Don’t Wanna Be Anywhere Near The Stock’ In 4 Years, Feels WWDC Was Like A ‘Snap CEO Talking Like We’re Gonna Target 22-Year Olds’

    “He is at an age where more and more diseases are going to appear,” said Kitakata, who is single and has a grown son. “So being able to consult the vet but still reduce the number of visits to the hospital is very important for him and for me.”

    Kitakata’s decision to use CatsMe! reflects the growing trend of AI integration in healthcare. The app, developed by tech startup Carelogy and researchers at Nihon University, has been used by over 230,000 customers since its launch last year.

    It is trained on 6,000 pictures of cats and is reportedly more than 95% accurate in detecting feline pain. The developers expect this accuracy to improve as the AI trains on more feline faces.

    According to Kazuya Edamura, a professor at Nihon University, CatsMe! can help cat owners become aware of their pet’s health status. This is particularly important in Japan, where pets play an outsized role due to the aging population and declining birth rate.

    The Japan Pet Food Association estimated that there were almost 16 million pet cats and dogs in the country last year, more than the number of children under 15.

    Subscribe to the Benzinga Tech Trends newsletter to get all the latest tech developments delivered to your inbox.

    Why It Matters: The use of AI in the healthcare sector is rapidly expanding, with the global AI in healthcare market size projected to reach $148.4 billion by 2029. This growth is driven by the multifaceted benefits AI offers, including streamlining administrative tasks, optimizing treatment plans, and enabling more precise diagnostics.

    AI is also making waves in other areas of healthcare. For instance, in March earlier this year, it was announced that Nvidia Corporation partnered with Hippocratic AI to introduce AI nurses that charge a mere $9 per hour, a significant contrast to the average $90 per hour fee for human nurses.

    Companies like Cardio Diagnostics Hldgs are also using AI to help prevent cardiovascular disease, which is the leading cause of death for men, women, and people of most racial and ethnic groups in the U.S.

    Check out more of Benzinga’s Consumer Tech coverage by following this link.

    Read Next: Apple Unveils iOS 18 With Satellite Messaging, Home Screen Customization, Privacy Improvements And More

    Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.

    Get the next $BNAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNAI
    $CDIO
    $NVDA

    CompanyDatePrice TargetRatingAnalyst
    NVIDIA Corporation
    $NVDA
    1/15/2026$240.00Outperform
    RBC Capital Mkts
    NVIDIA Corporation
    $NVDA
    11/21/2025$272.00Strong Buy
    Raymond James
    NVIDIA Corporation
    $NVDA
    11/20/2025$225.00 → $275.00Outperform
    Robert W. Baird
    NVIDIA Corporation
    $NVDA
    11/20/2025$240.00 → $250.00Buy
    Jefferies
    NVIDIA Corporation
    $NVDA
    11/20/2025$220.00 → $250.00Buy
    The Benchmark Company
    NVIDIA Corporation
    $NVDA
    11/20/2025$228.00 → $255.00Buy
    Truist
    NVIDIA Corporation
    $NVDA
    11/20/2025$180.00 → $215.00Hold
    Deutsche Bank
    NVIDIA Corporation
    $NVDA
    11/20/2025$220.00 → $270.00Buy
    Citigroup
    More analyst ratings

    $BNAI
    $CDIO
    $NVDA
    SEC Filings

    View All

    Brand Engagement Network Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Brand Engagement Network Inc. (0001838163) (Filer)

    3/31/26 6:20:19 AM ET
    $BNAI
    EDP Services
    Technology

    SEC Form NT 10-K filed by Brand Engagement Network Inc.

    NT 10-K - Brand Engagement Network Inc. (0001838163) (Filer)

    3/31/26 6:15:10 AM ET
    $BNAI
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by NVIDIA Corporation

    SCHEDULE 13G/A - NVIDIA CORP (0001045810) (Subject)

    3/26/26 11:52:04 AM ET
    $NVDA
    Semiconductors
    Technology

    $BNAI
    $CDIO
    $NVDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on NVIDIA with a new price target

    RBC Capital Mkts initiated coverage of NVIDIA with a rating of Outperform and set a new price target of $240.00

    1/15/26 8:38:56 AM ET
    $NVDA
    Semiconductors
    Technology

    Raymond James resumed coverage on NVIDIA with a new price target

    Raymond James resumed coverage of NVIDIA with a rating of Strong Buy and set a new price target of $272.00

    11/21/25 8:11:09 AM ET
    $NVDA
    Semiconductors
    Technology

    Robert W. Baird reiterated coverage on NVIDIA with a new price target

    Robert W. Baird reiterated coverage of NVIDIA with a rating of Outperform and set a new price target of $275.00 from $225.00 previously

    11/20/25 9:03:55 AM ET
    $NVDA
    Semiconductors
    Technology

    $BNAI
    $CDIO
    $NVDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Technology Officer Dogan Timur bought $20,000 worth of shares (68,965 units at $0.29) (SEC Form 4)

    4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    10/9/24 1:18:30 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: Chief Executive Officer Dogan Meeshanthini bought $20,000 worth of shares (68,965 units at $0.29) (SEC Form 4)

    4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    10/8/24 10:42:31 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: Chief Executive Officer Dogan Meeshanthini bought $20,000 worth of shares (68,965 units at $0.29) (SEC Form 4)

    4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    10/7/24 11:29:46 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BNAI
    $CDIO
    $NVDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Fung Peter K

    4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    4/2/26 2:21:52 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Betts Wendy J

    4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    4/2/26 2:18:23 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Intrater James

    4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

    4/2/26 2:08:32 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BNAI
    $CDIO
    $NVDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Robotics and AI in Drug Manufacturing: May Unlock Efficiency Gains, Long-Term Value

    AUSTIN, Texas, April 09, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: Pharmaceutical manufacturing is entering a period of structural transformation as regulators impose increasingly stringent expectations around contamination control, data integrity and operational traceability. The European Union's updated GMP Annex 1 guidance places strong emphasis on minimizing human involvement and implementing comprehensive contamination control strategies, requiring manufacturers to evaluate and mitigate risks across personnel, processes and environments. It also encourages the use of barrier systems and automation technologies, reflecting the widely accepted understanding that human oper

    4/9/26 8:30:00 AM ET
    $AMZN
    $JNJ
    $NVDA
    Catalog/Specialty Distribution
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IBN Initiates Coverage of Cardio Diagnostics Holdings Inc.

    AUSTIN, Texas, April 08, 2026 (GLOBE NEWSWIRE) -- via IBN -- Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, has engaged IBN, a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy. Cardio Diagnostics develops and commercializes blood-based clinical tests and data solutions designed to support the prevention, detection, and management of cardiovascular disease. Its approach integrates epigenetic and genetic biomarkers with artificial intel

    4/8/26 8:30:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    AI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory Standards

    AUSTIN, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: As regulatory expectations intensify and manufacturing complexity grows, pharmaceutical companies are moving beyond traditional quality systems toward a new paradigm: embedding artificial intelligence (AI) directly into operations as a real-time compliance layer. Rather than relying on retrospective audits and manual oversight, AI-driven systems now continuously monitor, validate and optimize production processes to align with evolving Good Manufacturing Practice (GMP) standards. This structural shift is increasingly visible across the industry and aligns with companies such as Oncotelic Therapeutics Inc. (OTC

    4/7/26 8:30:00 AM ET
    $AMZN
    $HON
    $NVDA
    Catalog/Specialty Distribution
    Consumer Discretionary
    Aerospace
    Industrials

    $BNAI
    $CDIO
    $NVDA
    Financials

    Live finance-specific insights

    View All

    NVIDIA Announces Financial Results for Fourth Quarter and Fiscal 2026

    Record quarterly revenue of $68.1 billion, up 20% from Q3 and up 73% from a year agoRecord quarterly Data Center revenue of $62.3 billion, up 22% from Q3 and up 75% from a year agoRecord full-year revenue of $215.9 billion, up 65% SANTA CLARA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NVIDIA (NASDAQ:NVDA) today reported record revenue for the fourth quarter ended January 25, 2026, of $68.1 billion, up 20% from the previous quarter and up 73% from a year ago. For fiscal 2026, revenue was $215.9 billion, up 65% from a year ago. For the quarter, GAAP and non-GAAP gross margins were 75.0% and 75.2%, respectively. For fiscal 2026, GAAP and non-GAAP gross margins were 71.1% and

    2/25/26 4:31:17 PM ET
    $NVDA
    Semiconductors
    Technology

    Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. Web

    2/17/26 8:35:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    NVIDIA Sets Conference Call for Fourth-Quarter Financial Results

    SANTA CLARA, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- NVIDIA will host a conference call on Wednesday, February 25, at 2 p.m. PT (5 p.m. ET) to discuss its financial results for the fourth quarter and fiscal year 2026, which ended January 25, 2026. The call will be webcast live (in listen-only mode) on investor.nvidia.com. The company's prepared remarks will be followed by a Q&A session, which will be limited to questions from financial analysts and institutional investors. Ahead of the call, NVIDIA will provide written commentary on its fourth-quarter results from Colette Kress, the company's executive vice president and chief financial officer. This material will be posted to investor

    1/28/26 5:00:00 PM ET
    $NVDA
    Semiconductors
    Technology

    $BNAI
    $CDIO
    $NVDA
    Leadership Updates

    Live Leadership Updates

    View All

    10 Federal Taps Top-Ranked Nvidia AI Engineer to Fill Self-Storage Industry's First Chief AI Officer Role

    Nvidia's top 1% AI engineer leaves world's most valuable company to lead self-storage's first Chief AI Officer role at 10 FederalRALEIGH, N.C., April 6, 2026 /PRNewswire/ -- 10 Federal, a leading technology-driven self-storage owner and operator, today announced the appointment of Christopher Taylor as its Chief A.I. Officer (CAIO), a newly created executive position that represents the first dedicated C-suite AI role in the self-storage industry. Taylor joins 10 Federal from Nvidia (NASDAQ:NVDA), the global leader in AI computing, where he served as a Senior Software Engineer working across both the data center division and the autonomous vehicle platform, and ranked among the top 1% of AI

    4/6/26 6:00:00 AM ET
    $NVDA
    Semiconductors
    Technology

    Palantir and NVIDIA Team Up to Operationalize AI — Turning Enterprise Data Into Dynamic Decision Intelligence

    News Summary Palantir is integrating NVIDIA accelerated computing, NVIDIA CUDA-X libraries and open-source NVIDIA Nemotron models into its Ontology framework at the core of the Palantir AI Platform.Lowe's is pioneering operational AI for its supply chain logistics with Palantir and NVIDIA. WASHINGTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- GTC Washington, D.C. -- NVIDIA today announced a collaboration with Palantir Technologies Inc. to build a first-of-its-kind integrated technology stack for operational AI — including analytics capabilities, reference workflows, automation features and customizable, specialized AI agents — to accelerate and optimize complex enterprise and government systems.

    10/28/25 1:36:17 PM ET
    $NVDA
    Semiconductors
    Technology

    BEN Appoints Dr. Ruy Carrasco to Board; Company to Debut Insurance AI Agent at Swiss Life Network Partners Conference in London

    WILMINGTON, Del., Sept. 19, 2025 /PRNewswire/ -- Brand Engagement Network, Inc. (NASDAQ:BNAI) ("BEN"), an innovator in human-like AI Agents for regulated industries, announced the appointment of Ruy Carrasco, M.D. to its Board of Directors, effective as of September 18, 2025. Dr. Carrasco, who has served as BEN's Chief Medical Informatics Officer since 2021, adds deep expertise in healthcare, informatics, and enterprise innovation to the Board. "BEN is advancing with discipline and delivering with the global partners we've secured across the U.S., LATAM, and the EU," said Tyle

    9/19/25 6:00:00 AM ET
    $BNAI
    EDP Services
    Technology

    $BNAI
    $CDIO
    $NVDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Brand Engagement Network Inc.

    SC 13G/A - Brand Engagement Network Inc. (0001838163) (Subject)

    11/14/24 12:51:16 PM ET
    $BNAI
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by NVIDIA Corporation

    SC 13G/A - NVIDIA CORP (0001045810) (Subject)

    11/12/24 10:32:12 AM ET
    $NVDA
    Semiconductors
    Technology

    SEC Form SC 13D filed by Brand Engagement Network Inc.

    SC 13D - Brand Engagement Network Inc. (0001838163) (Subject)

    7/26/24 7:58:52 PM ET
    $BNAI
    EDP Services
    Technology